Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 19/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12127019 | 1.00 | XPO1 (0.64) | XPO1HDAC1HDAC6 | |
| SCHEMBL1336285 | 1.00 | XPO1 (0.64) | XPO1HDAC1HDAC6 | |
| SCHEMBL16282014 | 0.88 | XPO1 (0.64) | XPO1 | |
| SCHEMBL26326400 | 0.88 | XPO1 (0.64) | XPO1 | |
| SCHEMBL1333953 | 0.88 | XPO1 (0.73) | XPO1 | |
| SCHEMBL1333949 | 0.88 | XPO1 (0.73) | XPO1 | |
| SCHEMBL1335010 | 0.88 | XPO1 (0.73) | XPO1 | |
| SCHEMBL20724222 | 0.85 | XPO1 (0.57) | XPO1HDAC1HDAC6 | |
| SCHEMBL1333731 | 0.85 | XPO1 (0.72) | XPO1HDAC1HDAC6 | |
| SCHEMBL1333732 | 0.85 | XPO1 (0.72) | XPO1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | claimed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2968278-B1 | METHODS OF PROMOTING WOUND HEALING USING CRM1 INHIBITORS | KARYOPHARM THERAPEUTICS INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.